252 related articles for article (PubMed ID: 16804112)
1. JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model.
Mercher T; Wernig G; Moore SA; Levine RL; Gu TL; Fröhling S; Cullen D; Polakiewicz RD; Bernard OA; Boggon TJ; Lee BH; Gilliland DG
Blood; 2006 Oct; 108(8):2770-9. PubMed ID: 16804112
[TBL] [Abstract][Full Text] [Related]
2. Activating alleles of JAK3 in acute megakaryoblastic leukemia.
Walters DK; Mercher T; Gu TL; O'Hare T; Tyner JW; Loriaux M; Goss VL; Lee KA; Eide CA; Wong MJ; Stoffregen EP; McGreevey L; Nardone J; Moore SA; Crispino J; Boggon TJ; Heinrich MC; Deininger MW; Polakiewicz RD; Gilliland DG; Druker BJ
Cancer Cell; 2006 Jul; 10(1):65-75. PubMed ID: 16843266
[TBL] [Abstract][Full Text] [Related]
3. FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model.
Grundler R; Miething C; Thiede C; Peschel C; Duyster J
Blood; 2005 Jun; 105(12):4792-9. PubMed ID: 15718420
[TBL] [Abstract][Full Text] [Related]
4. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
[TBL] [Abstract][Full Text] [Related]
5. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.
Kelly LM; Liu Q; Kutok JL; Williams IR; Boulton CL; Gilliland DG
Blood; 2002 Jan; 99(1):310-8. PubMed ID: 11756186
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine 201 is required for constitutive activation of JAK2V617F and efficient induction of myeloproliferative disease in mice.
Yan D; Hutchison RE; Mohi G
Blood; 2012 Aug; 120(9):1888-98. PubMed ID: 22837531
[TBL] [Abstract][Full Text] [Related]
7. The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model.
Mercher T; Raffel GD; Moore SA; Cornejo MG; Baudry-Bluteau D; Cagnard N; Jesneck JL; Pikman Y; Cullen D; Williams IR; Akashi K; Shigematsu H; Bourquin JP; Giovannini M; Vainchenker W; Levine RL; Lee BH; Bernard OA; Gilliland DG
J Clin Invest; 2009 Apr; 119(4):852-64. PubMed ID: 19287095
[TBL] [Abstract][Full Text] [Related]
8. Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome.
Malinge S; Bliss-Moreau M; Kirsammer G; Diebold L; Chlon T; Gurbuxani S; Crispino JD
J Clin Invest; 2012 Mar; 122(3):948-62. PubMed ID: 22354171
[TBL] [Abstract][Full Text] [Related]
9. Activating mutations in human acute megakaryoblastic leukemia.
Malinge S; Ragu C; Della-Valle V; Pisani D; Constantinescu SN; Perez C; Villeval JL; Reinhardt D; Landman-Parker J; Michaux L; Dastugue N; Baruchel A; Vainchenker W; Bourquin JP; Penard-Lacronique V; Bernard OA
Blood; 2008 Nov; 112(10):4220-6. PubMed ID: 18755984
[TBL] [Abstract][Full Text] [Related]
10. Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.
Greene ME; Mundschau G; Wechsler J; McDevitt M; Gamis A; Karp J; Gurbuxani S; Arceci R; Crispino JD
Blood Cells Mol Dis; 2003; 31(3):351-6. PubMed ID: 14636651
[TBL] [Abstract][Full Text] [Related]
11. The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3.
Spiekermann K; Dirschinger RJ; Schwab R; Bagrintseva K; Faber F; Buske C; Schnittger S; Kelly LM; Gilliland DG; Hiddemann W
Blood; 2003 Feb; 101(4):1494-504. PubMed ID: 12406902
[TBL] [Abstract][Full Text] [Related]
12. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model.
Wernig G; Mercher T; Okabe R; Levine RL; Lee BH; Gilliland DG
Blood; 2006 Jun; 107(11):4274-81. PubMed ID: 16478879
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic characteristics of acute megakaryocytic leukemia and transient abnormal myelopoiesis.
Yumura-Yagi K; Hara J; Tawa A; Kawa-Ha K
Leuk Lymphoma; 1994 May; 13(5-6):393-400. PubMed ID: 8069184
[TBL] [Abstract][Full Text] [Related]
14. Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome.
Sato T; Toki T; Kanezaki R; Xu G; Terui K; Kanegane H; Miura M; Adachi S; Migita M; Morinaga S; Nakano T; Endo M; Kojima S; Kiyoi H; Mano H; Ito E
Br J Haematol; 2008 May; 141(5):681-8. PubMed ID: 18397343
[TBL] [Abstract][Full Text] [Related]
15. Loss-of-function JAK3 mutations in TMD and AMKL of Down syndrome.
De Vita S; Mulligan C; McElwaine S; Dagna-Bricarelli F; Spinelli M; Basso G; Nizetic D; Groet J
Br J Haematol; 2007 May; 137(4):337-41. PubMed ID: 17456055
[TBL] [Abstract][Full Text] [Related]
16. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21.
Rainis L; Bercovich D; Strehl S; Teigler-Schlegel A; Stark B; Trka J; Amariglio N; Biondi A; Muler I; Rechavi G; Kempski H; Haas OA; Izraeli S
Blood; 2003 Aug; 102(3):981-6. PubMed ID: 12649131
[TBL] [Abstract][Full Text] [Related]
17. Exome sequencing identifies putative drivers of progression of transient myeloproliferative disorder to AMKL in infants with Down syndrome.
Nikolaev SI; Santoni F; Vannier A; Falconnet E; Giarin E; Basso G; Hoischen A; Veltman JA; Groet J; Nizetic D; Antonarakis SE
Blood; 2013 Jul; 122(4):554-61. PubMed ID: 23733339
[TBL] [Abstract][Full Text] [Related]
18. A 15q24 microdeletion in transient myeloproliferative disease (TMD) and acute megakaryoblastic leukaemia (AMKL) implicates PML and SUMO3 in the leukaemogenesis of TMD/AMKL.
Haemmerling S; Behnisch W; Doerks T; Korbel JO; Bork P; Moog U; Hentze S; Grasshoff U; Bonin M; Rieß O; Janssen JW; Jauch A; Bartram CR; Reinhardt D; Koch KA; Bandapalli OR; Kulozik AE
Br J Haematol; 2012 Apr; 157(2):180-7. PubMed ID: 22296450
[TBL] [Abstract][Full Text] [Related]
19. Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation.
Aboudola S; Murugesan G; Szpurka H; Ramsingh G; Zhao X; Prescott N; Tubbs RR; Maciejewski JP; Hsi ED
Am J Surg Pathol; 2007 Feb; 31(2):233-9. PubMed ID: 17255768
[TBL] [Abstract][Full Text] [Related]
20. A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia.
Gu TL; Mercher T; Tyner JW; Goss VL; Walters DK; Cornejo MG; Reeves C; Popova L; Lee K; Heinrich MC; Rush J; Daibata M; Miyoshi I; Gilliland DG; Druker BJ; Polakiewicz RD
Blood; 2007 Jul; 110(1):323-33. PubMed ID: 17360941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]